Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.

Cai Y, Yi J, Zhou C, Shen X.

PLoS One. 2012;7(10):e47769. doi: 10.1371/journal.pone.0047769. Epub 2012 Oct 17.

2.

Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis.

Sun F, Chen Y, Xiang Y, Zhan S.

Int J Tuberc Lung Dis. 2008 Sep;12(9):994-1002. Review.

PMID:
18713495
3.

The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.

Xiang Y, Ma L, Wu W, Liu W, Li Y, Zhu X, Wang Q, Ma J, Cao M, Wang Q, Yao X, Yang L, Wubuli A, Merle C, Milligan P, Mao Y, Gu J, Xin X.

PLoS One. 2014 Jan 23;9(1):e85905. doi: 10.1371/journal.pone.0085905. eCollection 2014.

4.

CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study.

Tang SW, Lv XZ, Zhang Y, Wu SS, Yang ZR, Xia YY, Tu DH, Deng PY, Ma Y, Chen DF, Zhan SY.

J Clin Pharm Ther. 2012 Oct;37(5):588-93. doi: 10.1111/j.1365-2710.2012.01334.x. Epub 2012 Feb 15.

PMID:
22335459
5.

Genetic polymorphisms in metabolic enzymes and susceptibility to anti-tuberculosis drug-induced hepatic injury.

Feng FM, Guo M, Chen Y, Li SM, Zhang P, Sun SF, Zhang GS.

Genet Mol Res. 2014 Nov 11;13(4):9463-71. doi: 10.4238/2014.November.11.11.

6.

NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.

Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF.

Int J Tuberc Lung Dis. 2012 May;16(5):589-95. doi: 10.5588/ijtld.11.0377. Epub 2012 Mar 8. Review.

PMID:
22409928
7.

Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.

Singla N, Gupta D, Birbian N, Singh J.

Tuberculosis (Edinb). 2014 May;94(3):293-8. doi: 10.1016/j.tube.2014.02.003. Epub 2014 Feb 15.

PMID:
24637014
8.

Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.

Teixeira RL, Morato RG, Cabello PH, Muniz LM, Moreira Ada S, Kritski AL, Mello FC, Suffys PN, Miranda AB, Santos AR.

Mem Inst Oswaldo Cruz. 2011 Sep;106(6):716-24.

9.

Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury.

Huang YS.

J Chin Med Assoc. 2014 Apr;77(4):169-73. doi: 10.1016/j.jcma.2014.01.010. Epub 2014 Mar 1. Review.

10.

GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis.

Li C, Long J, Hu X, Zhou Y.

Eur J Clin Microbiol Infect Dis. 2013 Jul;32(7):859-68. doi: 10.1007/s10096-013-1831-y. Epub 2013 Feb 2. Review.

PMID:
23377313
11.

Antituberculosis drug-induced hepatitis: risk factors, prevention and management.

Hussain Z, Kar P, Husain SA.

Indian J Exp Biol. 2003 Nov;41(11):1226-32. Review.

PMID:
15332488
12.

Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.

Perwitasari DA, Darmawan E, Mulyani UA, Vlies PV, Alffenaar JC, Atthobar J, Wilffert B.

Int J Mycobacteriol. 2018 Oct-Dec;7(4):380-386. doi: 10.4103/ijmy.ijmy_143_18.

13.

GSTM1 and GSTT1 null polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.

Tang N, Deng R, Wang Y, Lin M, Li H, Qiu Y, Hong M, Zhou G.

Int J Tuberc Lung Dis. 2013 Jan;17(1):17-25. doi: 10.5588/ijtld.12.0447.

PMID:
23232001
14.

N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians.

Rana SV, Sharma SK, Ola RP, Kamboj JK, Malik A, Morya RK, Sinha SK.

J Clin Pharm Ther. 2014 Feb;39(1):91-6. doi: 10.1111/jcpt.12105. Epub 2013 Nov 5.

PMID:
24188272
15.

Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.

Costa GN, Magno LA, Santana CV, Konstantinovas C, Saito ST, Machado M, Di Pietro G, Bastos-Rodrigues L, Miranda DM, De Marco LA, Romano-Silva MA, Rios-Santos F.

Mol Diagn Ther. 2012 Aug 1;16(4):241-50. doi: 10.2165/11634480-000000000-00000.

PMID:
22788240
16.

Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.

Shi J, Xie M, Wang J, Xu Y, Liu X.

Pharmacogenomics. 2015 Dec;16(18):2083-97. doi: 10.2217/pgs.15.144. Epub 2015 Nov 30.

PMID:
26616266
17.

Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.

Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, Ramegowda PH, Amarapurkar AD, Joshi K, Wangikar PP.

J Gastroenterol Hepatol. 2013 Aug;28(8):1368-74. doi: 10.1111/jgh.12194.

PMID:
23875638
18.

NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.

An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y.

Clin Exp Pharmacol Physiol. 2012 Jun;39(6):535-43. doi: 10.1111/j.1440-1681.2012.05713.x.

PMID:
22506592
19.
20.

Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis.

Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P.

J Gastroenterol Hepatol. 2011 Feb;26(2):312-8. doi: 10.1111/j.1440-1746.2010.06355.x.

PMID:
21261721

Supplemental Content

Support Center